ZOFRAN ZOFRAN ZOFRAN ZOFRAN OPTRA ONDEN ONDEN ONDEN ONDANSETRON ONDAMEX ONDANLES ONDANLES ONDANLES ONDANLES ONDANLES ONSET ONSET ONDISON ONDIEMETIC ONDERON ONDERON ONDERON SR SETRON O-TRON ONDAVELL ® SHARON SHARON Averon ODANSO OSETRON OSETRON ANOMED ONDIGO ONIRON ONIRON ESPASEVIT ESPASEVIT DANWRD NES-8

Dose: 0.15 to 0.45 mg/ kg
Single Dose: 0.3 (0.3)
Frequency: 4 hourly
Route: IV
Instructions: Max. Dose =32 mg. Give 30 Min. before emetogenic drugs.

Dose: 5 mg/m2
Single Dose: 5 (5)
Frequency: As recommended.
Route: IV Infusion
Instructions: Initially for 15 Min (Rec. for 5-12 Yrs)

. It is of Synthetic origin and belongs to Imidazole. It belongs to Antiemetic/Antivertigo Agents and Selective 5-HT3 Receptor Antagonist pharmacological group.The Molecular Weight of Ondansetron (HCl) is 365.80. Its pKa is 7.4.

Ondansetron (HCl) is contraindicated in conditions like Hypersensitivity.

The severe or irreversible adverse effects of Ondansetron (HCl), which give rise to further complications include Cardiac arrhythmias, Bronchospasm, Cardiac arrhythmias, Bradycardia, Bronchospasm, Angioedema, Angina, Angioedema, Hyperbilirubinemia.The symptomatic adverse reactions produced by Ondansetron (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fever, Dyspnea, Constipation, Abdominal pain, Chills, Hypotension, Flushing, Hiccups, Xerostomia, Vision disturbances, Reaction at injection site, Warmth sensation, dizziness, Hypotension.

Ondansetron (HCl) is primarily indicated in conditions like Moderately emetognic chemotherapy or radiotherapy, Nausea and vomiting (chemotherapy induced), Post operative vomiting, Post-operative nausea, Post-operative nausea and vomiting, Prevention of post-operative nausea and vomiting, Severely emetognic chemotherapy.

Ondansetron (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCarbamazepineBy concurrent use the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.No dosage adjustment for ondansetron is recommended for patients on these drugs.IndacaterolBoth indacaterol and ondansetron prolong the QT intervalconsider alternate therapyPhenytoin (Na)By concurrent use the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.No dosage adjustment for ondansetron is recommended for patients on these drugs.RifampicinBy concurrent use the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.No dosage adjustment for ondansetron is recommended for patients on these drugs.Tramadol (HCl)post operative analgesic activity of tramadol is decreased. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

No technical interferance have been reported

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj (reconstituted soln) Store at room temperature. Use within 24-48 hrs if kept at room temperature. Tab, Syrup, Suppositories Store at room temperature. Protect from Sunlight.

Dosage restriction is advisable in patients with moderate to severe liver impairment. Ondansetron should be used with caution during pregnancy or lactation. Care is required in the patient exhibiting hypersensitivity to other selective 5HT3 receptor antagonists and in patient with signs of subacute intestinal obstruction.